Open Access Highly Accessed Open Badges Study protocol

A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II)

Akira Tsuburaya1*, Satoshi Morita2, Yasuhiro Kodera3, Michiya Kobayashi4, Kohei Shitara5, Kensei Yamaguchi6, Takaki Yoshikawa1, Kazuhiro Yoshida7, Shigefumi Yoshino8 and Jun-ichi Sakamoto9

Author Affiliations

1 Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 1-1-2 Nakao, 241-0815, Yokohama, Asahi-ku, Japan

2 Department of Biostatistics and Epidemiology, Yokohama City University Medical Center, Yokohama, Japan

3 Department of Surgery II, Nagoya University Graduate School of Medicine, Nagoya, Japan

4 Department of Surgery, Kochi Medical School, Kochi, Japan

5 Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan

6 Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan

7 Department of Surgical Oncology, Gifu Graduate School of Medicine, Gifu, Japan

8 Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine, Ube, Japan

9 Epidemiological and Clinical Research Information Network, Nagoya University Graduate School of Medicine, Aichi, Nagoya, Japan

For all author emails, please log on.

BMC Cancer 2012, 12:307  doi:10.1186/1471-2407-12-307

Published: 23 July 2012



On the basis of international clinical trials, capecitabine plus cisplatin (XP) as a first-line treatment of advanced gastric cancer is considered a global standard regimen. However, the usefulness of XP as compared with S-1 plus cisplatin (SP), which is considered standard therapy in Japan, has not yet been assessed.


This is a multicenter randomized phase II trial to elucidate the efficacy of XP as compared with SP for first-line treatment of advanced gastric cancer. Patients with unresectable metastatic or recurrent gastric cancer, 20–74 years of age and human epidermal growth factor 2 (HER2)-negative status, will be assigned in a 1:1 ratio to receive either S-1 40 mg/m2 bid for 21 days plus cisplatin 60 mg/m2 (day 8) every 5-week cycle or capecitabine 1000 mg/m2 bid for 14 days plus cisplatin 80 mg/m2 (day 1) every 3-week cycle. Patients will be also asked to the analysis of tumor tissues for translational investigations. The Primary endpoint is progression-free survival and secondary endpoints are overall survival, time to treatment failure, tumor response rate and safety. These comparisons will also be evaluated in terms of biomarkers. Planned sample size is 100 (50 in each arm), which is appropriate for this trial.


Fluoropyrimidine plus cisplatin combination is the standard regimen of the first line treatment for advanced gastric cancer. Both S-1 and capecitabine are the prodrug of 5-FU but differ from their process of metabolism. Result of this trial and translational research will provide the important clues to prepare the individualized therapy for advanced gastric cancer in the near future.

Trial registration Identifier NCT01406249

Biomarker; Capecitabine; Cisplatin; Clinical trial; Gastric cancer; S-1